About Us

Our team is committed to enhancing our understanding of human disease.

Technology

Transforming the measurement of disease progression in vivo using noninvasive biosensors.

Pipeline

Bioengineered, tunable sensors that are designed for each protease-mediated disease.

Partners

Evolving the way diseases are understood, tracked and treated to accelerate the development of drugs.

News & Events

Transforming the way diseases are detected, tracked, treated, and understood.

Careers

Leveraging the profound advances in engineering, medicine, biotechnology, and machine learning.

Contact Us

We are proud to be members of the pre-eminent Cambridge biotech community.

News & Events

Transforming the way diseases are detected, tracked, treated, and understood.

Press Releases

  1. November 13, 2020

    First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual Meeting
  2. November 10, 2020

    Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting
  3. July 15, 2020

    Glympse Bio Announces $46.7 Million Series B Financing
  4. November 8, 2019

    Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management
  5. November 4, 2019

    Glympse Bio, Inc. Names Tracey Dawson as Chief Commercial Officer and Head of Strategy
  6. October 28, 2019

    Gilead and Glympse Bio Announce Strategic Collaboration For Use of Biomarker Technology in NASH Clinical Development

  7. August 1, 2019

    Pharmaceutical Executive Francis Cuss Joins Glympse Bio Board
  8. May 14, 2019

    Glympse Bio, Inc. Names Wendy Winckler as Chief Scientific Officer
  9. February 11, 2019

    Glympse Bio, Inc. Named to FierceMedTech’s “Fierce 15”
  10. December 4, 2018

    Glympse Bio, Inc. Appoints Caroline J. Loew, Ph.D. President and Chief Executive Officer
  11. October 3, 2018

    Glympse Bio, Inc. Raises $22m Series A Financing
More

News

  1. BioSpace

    Glympse Advances BioSensors for NASH and Other Protease-Mediated Diseases
  2. Decision Resource Group

    How Glympse Bio oversubscribed their Series B funding amidst the pandemic
  3. Fierce MedTech

    Glympse Bio clears first-in-human safety study of its injectable biosensors
  4. BioSpace

    On the Heels of $46.7 Million Financing, Glympse Bio Announces Positive Data for NASH Sensors
  5. MedTech Intelligence

    Advancing the Biopsy: Biosensors as a More Accurate and Sensitive Disease State Diagnostic Tool
  6. BioProcess Online

    Biosensors & Big Data: Implications For Biologics Developers
  7. 360Dx

    Glympse Bio Platform Enters Trials for Liver Disease Diagnosis, Treatment Monitoring
  8. STAT+

    Startup Spotlight: Glympse Bio hopes its test will show whether drugs are actually working
  9. ENDPOINTS News

    Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors
  10. BioCentury

    Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH
  11. MedCity News

    Glympse Bio raises more than $46M in Series B round for biosensor technology
  12. FierceBiotech

    Glympse Bio secures $46M to boost its injectable diagnostics for NASH, cancer & more
  13. The Wall Street Journal | Dow Jones

    Glympse Bio Raises $46.7 Million in Series B Funding Round
  14. BioWorld MedTech

    Glympse Bio snags $46.7M to advance biosensor platform
  15. BioSpace

    Glympse Bio Secures $46.7 Million to Advance NASH Biosensor Program
  16. 360Dx

    Glympse Bio Closes $46.7M Series B Financing
  17. FierceBiotech

    Glympse Bio, Inc. Named to FierceMedTech’s “Fierce 15”
  18. Youtube

    Sangeeta Bhatia Speaks at the 2018 National Academy of Sciences Meeting

  19. MIT News

    New Technology Can Detect Tiny Ovarian Tumors
  20. NAS

    Sangeeta Bhatia Inducted into the National Academy of Sciences (NAS)
  21. Xconomy

    Sangeeta Bhatia Winner of the "Innovation at the Intersection" Xconomy Award
  22. Georgia Tech

    Gabe Kwong Receives NIH Director’s New Innovator Award
  23. MIT News

    Nanosensors Could Help Determine Tumors’ Ability to Remodel Tissue
  24. Scientific American

    LEGO Dr. Bhatia
  25. MIT News

    A Paper Diagnostic for Cancer
  26. MIT News

    Finding Blood Clots Before They Wreak Havoc
  27. YouTube

    New Nanoparticle Detects Harmful Blood Clots (Video)
  28. MIT News

    New Technology May Enable Earlier Cancer Diagnosis
More

Publications

  1. Hepatic Protease Gene Expression Analysis to Predict Advanced Fibrosis in Patients with NASH: a Cross-validation Study

    Cazanave, S, Pacula, M, Huang, E, Kwong, G, Luther, J, Chung, R, Corey, K, Daly, A, Anstee, Q, Govaere, O, Winckler, W

  2. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease

    Kwong, GA, von Maltzahn, G, Murugappan, G, Abudayyeh, O, Mo, S, Papayannopoulos, IA, Sverdlov, DY, Liu, SB, Warren, AD, Popov, Y, Schuppan, and Bhatia, SN (2012): Nature Biotechnology. 1: 63-70.

  3. Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis

    Lin KY, Kwong GA, Warren AD, Wood DK, Bhatia SN (2013): ACS Nano. 7(10): 9001-9009.

  4. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics

    Warren, AD†, Kwong, GA†, Wood, DK†, Lin, KY, and Bhatia, SN (2014): PNAS. 111(10): 3671-3676.

  5. Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers

    Warren, AD†, Gaylord, ST†, Ngan, KC, Milutinovic, MD, Kwong, GA, Bhatia, SN‡, and Walt, DR‡ (2014): JACS. 136(39): 13709-13714.

  6. Mathematical framework for activity-based cancer biomarkers

    Kwong, GA, Dudani, JS, Carrodeguas, E, Mazumdar, EV, Zekavat, SM, and Bhatia, SN (2015): PNAS. 112(41): 12627-12632.

  7. Photoactivated spatiotemporally-responsive nanosensors of in vivo protease activity

    Dudani, JS, Jain, PK, Kwong, GA, Stevens, KR, and Bhatia, SN (2015): ACS Nano. 9(12): 11708-11717

  8. Sustained-release synthetic biomarkers for monitoring thrombosis and inflammation using point-of-care compatible readouts

    Dudani, JS, Buss, CG, Akana, RT, Kwong, GA, and Bhatia, SN (2016): Advanced Functional Materials. 26(17): 2919-2928

  9. Magnetically actuated protease sensors for in vivo tumor profiling

    Schuerle, S, Dudani, JS, Christiansen, MG, Anikeeva, P, and Bhatia, SN (2016): Nano Letters. 16(10): 6303-6310

  10. Ultrasensitive tumour-penetrating nanosensors of protease activity

    Kwon, EJ, Dudani, JS, and Bhatia, SN (2017): Nature Biomedical Engineering. 1. 54.

  11. Classification of prostate cancer using a protease activity nanosensor library

    Dudani. JS, Ibrahima M, Kirkpatrick J, Warren A, and Bhatia SN (2018): PNAS. 10.1073

  12. Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis (NASH)

    Sophie Cazanave, Maciej Pacula, Anna Zagorska, Andrew Warren, Sarah Sherman, Eric Huang, Katie Walker, Kathy Liu, David Lopez, David Newstrom, Shiva Zaboli, Jamie Bates, John T Liles,Grant R Budas, David G Breckenridge, Andrew Billin, Gabriel A. Kwong (2019): Presented at AASLD 2019
More

Events

No new events at this time.

Social Media

GlympseBioGlympse Bio@GlympseBio·
5 Jan

#GlympseBio is powered by our diverse team, innovative ideas, and disruptive technology. Our values guide us in our mission to enhance our understanding of human disease.

Learn more about our values and leadership: https://glympsebio.com/about-us/

Twitter 1346492534382620673
GlympseBioGlympse Bio@GlympseBio·
21 Dec

Our #biosensors are designed to measure the disease trajectory of #NASH and other fibrotic diseases as a noninvasive alternative to biopsy.

Learn more about #GlympseBio technology: https://glympsebio.com/technology/

Twitter 1341062692044476416
GlympseBioGlympse Bio@GlympseBio·
15 Dec

Recently #GlympseBio CEO Dr. Caroline Loew sat down with @BioPharmaMike on @DRGInsights’ “Conversations in Healthcare” series to discuss our technology in development and response to #COVID19.

Watch now: https://decisionresourcesgroup.com/downloads/glympse-bio-oversubscribed-series-b-funding-amidst-pandemic/

Twitter 1338853852246925312
GlympseBioGlympse Bio@GlympseBio·
24 Nov

Early detection of #NAFLD is key to preventing the onset of #NASH. #GlympseBio is committed the development of our repeatable, noninvasive disease detection platform to better understand disease progression.

Learn more from @liverUSA: https://liverfoundation.org/wp-content/uploads/2018/04/ALF-NAFLD-NASH-Infographic.pdf

Twitter 1331288099691892737